Robust CRO Market Is Driving New Merger and Acquisition Activity

Published on: 
Pharmaceutical Technology, Pharmaceutical Technology-12-02-2004, Volume 28, Issue 11

The blockage in the new product pipeline may be breaking. CROs report increased demand for late-stage development services in their latest round of earnings reports.

Related Content:

Bio/Pharma BusinessOutsourcingOutsourcing OutlookContract Manufacturing, GeneralPharmaceutical Technology-12-02-2004
Charles River to Provide pDNA Manufacturing Services in Two Deals
Lonza Forms Agreement to Manufacture Acumen Pharmaceuticals’ AD mAb Therapy
Genmab Expands ADC Pipeline with $1.8 Billion Acquisition of ProfoundBio